Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Conditions

• Non Small Cell Lung Cancer
• EGFR Gene Mutation
• Non Small Cell Lung Cancer Stage IIIB
• Non-small Cell Lung Cancer Stage IV

Interventions

• DRUG: Osimertinib

Sponsor

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University